COVID-19 rebound after VV116 vs nirmatrelvir-ritonavir treatment
About The Study: In this randomized clinical trial of 345 patients with mild-to-moderate COVID-19, viral load rebound and symptom rebound were both common after a standard 5-day course of antiviral treatment with either VV116 or nirmatrelvir-ritonavir. Prolongation of treatment duration might be investigated to reduce COVID-19 rebound.
Authors: Yufang Bi, M.D., and Yiping Xu, M.Sc., of the Shanghai Jiao Tong University School of Medicine in Shanghai, China, are the corresponding authors.
To access the embargoed study: Visit our For ...









